logo
A Pilates expert says these are the 8 best exercises for longevity to 'help you stay healthy in later life'

A Pilates expert says these are the 8 best exercises for longevity to 'help you stay healthy in later life'

Yahoo2 days ago
When you buy through links on our articles, Future and its syndication partners may earn a commission.
If you want to live a longer, more fulfilling life – aka being able to bend down and pick something up without straining your lower back – then building a stronger, more mobile body should be a top priority. Pilates is a great way to achieve this, as it helps improve and maintain our musculoskeletal health. According to Lotty Campbell Bird, founder of The Collective Fitness Studio, this is key to helping you 'stay fit, strong, and healthy in later life.'
'Musculoskeletal health is crucial for longevity because it enables mobility, independence, and overall well-being, all of which are vital for healthy ageing,' she explains. 'Strong muscles, bones, and joints allow you to perform daily tasks, maintain an active lifestyle, and reduce the risk of falls and injuries, which can significantly impact quality of life and lifespan.'
In order to help you build a stronger, resilient body, Lotty has shared eight Pilates exercises that will help enhance your musculoskeletal health. 'These exercises build core strength and postural alignment, which supports your spine and joints, prevents musculoskeletal deterioration that is common when aging, and help to maintain bone density.' Make sure you give the video above a quick watch if you're unfamiliar with the exercises (FYI, the video has been sped up, so make sure you take them slow).
Focus: Spinal articulation, core engagement, glute and hamstring activation.
How to:
Lie on your back, knees bent, feet flat
Inhale to prepare, exhale to slowly roll your spine off the mat one vertebra at a time
Inhale at the top, exhale to roll back down
Benefits: Improves spinal mobility, strengthens posterior chain.
Reps: 8-10
Focus: Glutes, hamstrings, spinal support, pelvic stability.
How to do it:
From a bridge position, lift one leg off the mat into tabletop while maintaining level hips
Alternate your legs
Benefits: Builds leg strength and improves balance, preventing hip and lower back dysfunction.
Reps: 5-6 each side
Focus: Deep core muscles (transversus abdominis and pelvic floor).
How to do it:
Lie on your back, lift legs to tabletop or straight up, curl head and shoulders off the mat.
Pulse arms vigorously up and down as you inhale for 5 counts, exhale for 5.
Benefits: Activates your deep core stabilisers and helps support posture.
Reps: x 10 cycles of breath
Focus: Improving core control and boosting hip mobility.
How to do it:
Lie on your back, with your head and shoulders curled up
Alternate legs as one pulls in, the other reaches long
Benefits: Strengthens abdominals while improving hip mobility and coordination.
Reps: 8-10 each side
Focus: Back extensor muscles, shoulder stabilisers and glutes.
How to do it:
Lie face down, hands under your forehead and legs extended.
Lift upper back off the ground, keeping your eyeline on the floor and your feet and legs still.
Benefits: Supports spinal extension, counters forward postures, and improves muscular balance.
Reps: 8-10 reps
Focus: Hip stability, glute medius strength and pelvic alignment.
How to do it:
Lie on your side with one arm tucked under your head for support and stack hips on top of one another
Lift top leg slowly with a flex and lower with control with a point
Benefits: Strengthens hip, helps with balance and offers lower back support.
Reps: 10-15 each leg
Focus: Spinal flexion, hamstring stretch, postural alignment.
How to do it:
Sit tall with legs extended and your feet flexed
Inhale to sit taller, exhale to reach forward from the spine
Benefits: Lengthens spine, reduces compression, increases flexibility.
Reps: 6-8
Focus: Stability of core and pelvis and hip mobility.
How to do it:
Lie on your back, one leg extended up, the other on the mat
Circle the raised leg while keeping hips stable
Benefits: Strengthens the core and improves hip joint range of motion without compromising the spine.
Reps: 8-10 each side
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

UK MHRA Approves ImmunityBio's ANKTIVA® Plus BCG for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ
UK MHRA Approves ImmunityBio's ANKTIVA® Plus BCG for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ

Yahoo

timean hour ago

  • Yahoo

UK MHRA Approves ImmunityBio's ANKTIVA® Plus BCG for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ

ANKTIVA, a first-in-class, lymphocyte-stimulating agent, works synergistically with BCG to activate and proliferate natural killer (NK) and T cells, helping eliminate cancer Already approved in the U.S. and designated as a Breakthrough Therapy by the FDA, this marks ANKTIVA's first marketing approval outside the U.S. ANKTIVA plus BCG offers a new option for eligible patients among the 16,400 to 18,000 people diagnosed with NMIBC in the UK each year1 CULVER CITY, Calif., July 08, 2025--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX) today announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorization for ANKTIVA® (nogapendekin alfa inbakicept-pmln) in combination with Bacillus Calmette-Guérin (BCG) for the treatment of certain bladder cancer patients. This is the first marketing approval outside the U.S. for this novel lymphocyte-stimulating agent. "With the MHRA's authorization of ANKTIVA plus BCG, we can now offer our immunotherapy outside the U.S. to help patients with a disease that, if not effectively treated, can lead to bladder removal," said Dr. Patrick Soon-Shiong, Founder, Executive Chairman and Global Chief Scientific and Medical Officer of ImmunityBio. "This immune-boosting, lymphocyte-stimulating agent, the first of its kind, is central to our Cancer BioShield platform, which is designed to restore immune function and support long-term disease control." "ImmunityBio is honored to have received this important authorization from the UK MHRA. In light of the United States Most-Favored-Nation Prescription Drug Pricing policy implemented on May 12, 2025, we are actively evaluating our go-to-market strategy for the UK," said Richard Adcock, CEO and President of ImmunityBio. ANKTIVA is a first-in-class IL-15 agonist that activates and proliferates natural killer (NK) cells and CD4+ and CD8+ T cells. It is designed to restore immune competence by reversing lymphopenia—a condition in which cancer and conventional therapies, such as chemotherapy, radiation and checkpoint inhibitors, reduce the number and function of immune cells. Restoring immune function is essential for immunosurveillance, immunogenic cell death, and sustained tumor control. The BioShield platform's effectiveness can be monitored using a routine complete blood count (CBC). ANKTIVA was designated a Breakthrough Therapy by the FDA and received approval from both the FDA and MHRA based on its safety and efficacy outcomes of complete response (CR) and duration of response (DOR). In a single-arm, multicenter trial, 77 evaluable patients received ANKTIVA with BCG for up to 37 months. As of the November 2023 data cutoff, the duration of complete response for some patients exceeded 47 months and remains ongoing. These extended duration of complete responses beyond 24 months with ANKTIVA and BCG surpasses the benchmark for meaningful clinical results set by experts from the International Bladder Cancer Group. ImmunityBio has also submitted regulatory applications to the European Medicines Agency (EMA) to expand availability of ANKTIVA across the 27 European Union (EU) member states, as well as Iceland, Norway and Liechtenstein. About NMIBC CIS Bladder cancer is the 10th most commonly-diagnosed cancer globally,2 and in the UK, the Action Bladder Cancer UK estimates approximately 23,000 patients are diagnosed annually.1 At the time of diagnosis, about 80% of cases are non-muscle invasive bladder cancer (NMIBC), wherein the cancer is found only on the inner layer of the bladder wall.3 The standard therapy for NMIBC is intravesical instillation (delivery to the bladder via a catheter) of Bacillus Calmette-Guerin (BCG).4,5 BCG is a benign bacteria that induces an immune response in the bladder in proximity to the cancer cells, leading to clearance of the cancer in many patients. In ~30-40% of patients, however, BCG will fail, and in ~50% that initially respond, cancer will recur.6 About ANKTIVA The cytokine interleukin-15 (IL-15) plays a crucial role in the immune system by affecting the development, maintenance, and function of key immune cells—NK and CD8+ killer T cells—that are involved in killing cancer cells. By activating NK cells, ANKTIVA overcomes the tumor escape phase of clones resistant to T cells and restores memory T cell activity with resultant prolonged duration of complete response. ANKTIVA is a first-in-class IL-15 agonist IgG1 fusion complex, consisting of an IL-15 mutant (IL-15N72D) fused with an IL-15 receptor alpha, which binds with high affinity to IL-15 receptors on NK, CD4+, and CD8+ T cells. This fusion complex of ANKTIVA mimics the natural biological properties of the membrane-bound IL-15 receptor alpha, delivering IL-15 by dendritic cells and drives the activation and proliferation of NK cells with the generation of memory killer T cells that have retained immune memory against these tumor clones. The proliferation of the trifecta of these immune killing cells and the activation of trained immune memory results in immunogenic cell death, inducing a state of equilibrium with durable complete responses. ANKTIVA has improved pharmacokinetic properties, longer persistence in lymphoid tissues, and enhanced anti-tumor activity compared to native, non-complexed IL-15 in-vivo. ANKTIVA was approved by the FDA in 2024 for BCG-unresponsive non-muscle invasive bladder cancer CIS with or without papillary tumors. For more information, visit INDICATION AND IMPORTANT SAFETY INFORMATION FROM THE FDA LABEL INDICATION AND USAGE: ANKTIVA is an interleukin-15 (IL-15) receptor agonist indicated with Bacillus Calmette-Guerin (BCG) for the treatment of adult patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors. WARNINGS AND PRECAUTIONS: Risk of Metastatic Bladder Cancer with Delayed Cystectomy. Delaying cystectomy can lead to the development of muscle invasive or metastatic bladder cancer, which can be lethal. If patient with CIS do not have a complete response to treatment after a second induction course of ANKTIVA with BCG, reconsider cystectomy. DOSAGE AND ADMINISTRATION: For lntravesical Use Only. Do not administer by subcutaneous or intravenous routes. Instill intravesically only after dilution. Total time from vial puncture to the completion of the intravesical instillation should not exceed 2 hours. USE IN SPECIFIC POPULATIONS: Pregnancy: May cause fetal harm. Advise females of reproductive potential of the potential risk to a fetus and to use effective contraception. ADVERSE REACTIONS: The most common (≥15%) adverse reactions, including laboratory test abnormalities, are increased creatinine, dysuria, hematuria, urinary frequency, micturition urgency, urinary tract infection, increased potassium, musculoskeletal pain, chills and pyrexia. For more information about ANKTIVA, please see the Full Prescribing Information at You are encouraged to report negative side effects of prescription drugs to FDA. Visit or call 1-800-332-1088. You may also contact lmmunityBio at 1-877-ANKTIVA (1-877-265-8482) About ImmunityBio ImmunityBio is a vertically-integrated biotechnology company developing next-generation therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. The Company's range of immunotherapy and cell therapy platforms, alone and together, act to drive and sustain an immune response with the goal of creating durable and safe protection against disease. Designated an FDA Breakthrough Therapy, ANKTIVA is the first FDA-approved immunotherapy for non-muscle invasive bladder cancer CIS that activates natural killer cells, T cells, and memory T cells for a long-duration response. The Company is applying its science and platforms to treating cancers, including the development of potential cancer vaccines, as well as developing immunotherapies and cell therapies that we believe sharply reduce or eliminate the need for standard high-dose chemotherapy. These platforms and their associated product candidates are designed to be more effective, accessible, and easily administered than current standards of care in oncology and infectious diseases. For more information, visit (Founder's Vision) and connect with us on X (Twitter), Facebook, LinkedIn, and Instagram. References: Action Bladder UK. Non-muscle invasive bladder cancer. May 2021. Available at: World Cancer Research Fund. Bladder Cancer Statistics. 2022. Available at: Aldousari S, Kassouf W. Update on the management of non-muscle invasive bladder cancer. Canadian Urological Association Journal, 4(1), 56–64. Holzbeierlein J, Bixler BR, Buckley DI, et al. Diagnosis and treatment of non-muscle invasive bladder cancer: AUA/SUO guideline: 2024 amendment. J Urol. 2024;10.1097/JU.0000000000003846. Grabe-Heyne, et al. Intermediate and high-risk non-muscle-invasive bladder cancer: an overview of epidemiology, burden, and unmet needs. Front Oncol. 2023 Jun 2;13:1170124. doi: 10.3389/fonc.2023.1170124. Kodera A, Mohammed M, Lim P, Abdalla O, Elhadi M. The Management of Bacillus Calmette-Guérin (BCG) Failure in High-Risk Non-muscle Invasive Bladder Cancer: A Review Article. Cureus. 2023 Jun 26;15(6):e40962. doi: 10.7759/cureus.40962. PMID: 37503461; PMCID: PMC10369196. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements regarding clinical trial data and potential results and implications to be drawn therefrom, the belief that the MHRA authorization leads to increased revenue, the expectation that the EAP as previously reported will enable access to ANKTIVA for patients across all solid tumor types who have exhausted first-line therapy including chemo, radiation or immunotherapy, the RMAT designation as previously reported and potential results therefrom and regulatory submissions in connection therewith, the belief that ALC levels and NLR levels obtained from a CBC are predictors of clinical benefit and outcomes relating to overall survival, the belief that improving ALC levels and NLR levels correlates with enhanced overall survival and clinical benefit, the belief that reversal of lymphopenia correlates with improved survival, clinical trial and expanded access program enrollment, data and potential results to be drawn therefrom, anticipated components of ImmunityBio's Cancer BioShield platform, the development of therapeutics for cancer and infectious diseases, potential benefits to patients, potential treatment outcomes for patients, the described mechanism of action and results and contributions therefrom, potential future uses and applications of ANKTIVA alone or in combination with other therapeutic agents for the prevention or reversal of lymphopenia, potential future uses and applications of ANKTIVA alone or in combination with other therapeutic agents across multiple tumor types and indications and for potential applications beyond oncology, potential regulatory pathways and the regulatory review process and timing thereof, the application of the Company's science and platforms to treat cancers or develop cancer vaccines, immunotherapies and cell therapies that has the potential to change the paradigm in cancer care, and ImmunityBio's approved product and investigational agents as compared to existing treatment options, and the impact of the MHRA on the Company's ex-United States go to market strategy, including in light of the recently implemented United States Most Favored Nation pricing policy on the Company's go-to-market strategy in the United Kingdom, among others. Statements in this press release that are not statements of historical fact are considered forward-looking statements, which are usually identified by the use of words such as "anticipates," "believes," "continues," "goal," "could," "estimates," "scheduled," "expects," "intends," "may," "plans," "potential," "predicts," "indicate," "projects," "is," "seeks," "should," "will," "strategy," and variations of such words or similar expressions. Statements of past performance, efforts, or results of our preclinical and clinical trials, about which inferences or assumptions may be made, can also be forward-looking statements and are not indicative of future performance or results. Forward-looking statements are neither forecasts, promises nor guarantees, and are based on the current beliefs of ImmunityBio's management as well as assumptions made by and information currently available to ImmunityBio. Such information may be limited or incomplete, and ImmunityBio's statements should not be read to indicate that it has conducted a thorough inquiry into, or review of, all potentially available relevant information. Such statements reflect the current views of ImmunityBio with respect to future events and are subject to known and unknown risks, including business, regulatory, economic and competitive risks, uncertainties, contingencies and assumptions about ImmunityBio, including, without limitation, (i) risks and uncertainties regarding the FDA regulatory submission, filing and review process and the timing thereof, (ii) risks and uncertainties regarding regulatory submissions in foreign jurisdictions, filing and review process and the timing thereof, (iii) whether the RMAT designation will lead to an accelerated review or approval, of which there can be no assurance, (iv) risks and uncertainties regarding commercial launch execution, success and timing, (v) risks and uncertainties regarding participation and enrollment and potential results from the expanded access clinical investigation program described herein, (vi) whether clinical trials will result in registrational pathways and the risks, (vii) whether clinical trial data will be accepted by regulatory agencies, (viii) the ability of ImmunityBio to continue its planned preclinical and clinical development of its development programs through itself and/or its investigators, and the timing and success of any such continued preclinical and clinical development, patient enrollment and planned regulatory submissions, (iv) potential delays in product availability and regulatory approvals, (x) ImmunityBio's ability to retain and hire key personnel, (xi) ImmunityBio's ability to obtain additional financing to fund its operations and complete the development and commercialization of its various product candidates, (xii) potential product shortages or manufacturing disruptions that may impact the availability and timing of product, (xiii) ImmunityBio's ability to successfully commercialize its approved product and product candidates, (xiv) ImmunityBio's ability to scale its manufacturing and commercial supply operations for its approved product and future approved products, and (xv) ImmunityBio's ability to obtain, maintain, protect, and enforce patent protection and other proprietary rights for its product candidates and technologies. More details about these and other risks that may impact ImmunityBio's business are described under the heading "Risk Factors" in the Company's Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) on March 3, 2025, and the Company's Form 10-Q filed with the SEC on May 12, 2025, and in subsequent filings made by ImmunityBio with the SEC, which are available on the SEC's website at ImmunityBio cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date hereof. View source version on Contacts ImmunityBio Contacts: Investors Hemanth Ramaprakash, PhD, MBA ImmunityBio, Inc. +1 Media Sarah Singleton ImmunityBio, Inc. +1 Sign in to access your portfolio

£749 handout from DWP if you have any of these 87 muscle or joint problems
£749 handout from DWP if you have any of these 87 muscle or joint problems

Yahoo

time2 hours ago

  • Yahoo

£749 handout from DWP if you have any of these 87 muscle or joint problems

Personal Independence Payment (PIP) is a benefit designed for people who require extra help with everyday tasks due to an illness, disability or mental health condition. It is worth up to £749.80 every four weeks and is handed out by the Department for Work and Pensions ( DWP ). PIP is not an out of work benefit, so you may be eligible for PIP if you are working at present, reports MirrorOnline. READ MORE: Nationwide, Barclays and NatWest customers handed £185 to switch with rival bank Get breaking news on BirminghamLive WhatsApp, click the link to join How much you could get in PIP all depends on how your condition your health condition or disability impacts your life. There is no official list of conditions that make you eligible for PIP. As per DWP data, there are more than one million adults who are in receipt of PIP for musculoskeletal conditions, out of the 3.7million who claim PIP overall. Musculoskeletal conditions are injuries and disorders that impact the body's movement or musculoskeletal system such as muscles, tendons, ligaments, nerves, discs and blood vessels. PIP is made up of two components - a daily living rate and a mobility rate - and you can be entitled to both or just one of these. If you are eligible for both the enhanced rate of the daily living allowance and the mobility allowance, you would receive £749.80 a month. Daily Living Standard rate: £73.90 a week Enhanced rate: £110.40 a week Mobility Standard rate: £29.20 a week Enhanced rate: £77.05 a week Osteoarthritis Osteoarthritis of Hip Osteoarthritis of Knee Osteoarthritis of other single joint Primary generalised Osteoarthritis Chronic pain syndrome Chronic fatigue syndrome (CFS) Fibromyalgia Pain syndromes - Chronic - Other / type not known Inflammatory arthritis Ankylosing spondylitis Arthritis - Psoriatic Arthritis - Reactive Inflammatory arthritis - Other / type not known Juvenile chronic arthritis (Still's disease) Rheumatoid arthritis Crystal deposition disorders Crystal deposition disorders - Other / type not known Gout Pseudogout Osteonecrosis and osteochondritis Osteochondritis Osteonecrosis Metabolic and endocrine disorders Osteomalacia Osteoporosis Other metabolic and endocrine disorders of musculoskeletal system Paget's disease Rickets Genetic disorders, dysplasias and malformations Achondroplasia Epiphyseal dysplasia - multiple Genetic disorders, dysplasias and malformations - Other / type not known Hereditary multiple exostosis (diaphyseal aclasis) Hypermobility syndrome Marfan's syndrome Osteogenesis imperfecta Benign tumours of bone Tumours of bone - benign Fracture complications Compartment syndrome (Volkmann's ischaemia) Fracture complications - Other / type not known Sudek's atrophy Other generalised musculoskeletal conditions Generalised musculoskeletal disease - Other / type not known Shoulder disorders Adhesive capsulitis (frozen shoulder) Rotator cuff disorder Shoulder disorders - Other / type not known Shoulder instability Elbow disorders Elbow disorders - Other / type not known Golfers elbow (medial epicondylitis) Tennis elbow (lateral epicondylitis) Wrist and hand disorders Carpal tunnel syndrome Dupuytren's contracture Tendon lesions Tenosynovitis Wrist and hand disorders - Other / type not known Neck disorders Cervical disc lesion Cervical spondylosis Neck disorders - Other / type not known Whiplash injury Non specific back pain Back pain - Non specific (mechanical) Specific back pain Back pain - Specific - Other / type not known Kyphosis Lumbar disc lesion Lumbar spondylosis (OA spine) Schuermann's disease Scoliosis Spinal stenosis Spondylolisthesis Hip disorders Dislocation of the hip - congenital Hip disorders - Other / type not known Perthes disease Slipped upper femoral epiphysis Knee disorders Bursitis Chondromalacia patellae Knee disorders - Other / type not known Ligamentous instability of knee Meniscal lesions Osgood schlatters disease Osteochondritis dissecans Patellar dislocation - Recurrent Ankle and foot disorders Ankle and foot disorders - Other / type not known Club foot (talipes) Fore foot pain (Metatarsalgia) Hallux valgus /rigidus Amputations Amputation - Lower limb(s) Amputation - Upper limb(s) Amputations - Upper & Lower limb/s Injuries/fracture/Dislocation Abdomen - Injuries/Fracture/Dislocation of Lower limb - Injuries/Fracture/Dislocation of Multiple - Injuries/Fracture/Dislocation Pelvis - Injuries/Fracture/Dislocation of Spine - Injuries/Fracture/Dislocation of Thorax - Injury/Fracture/Dislocation of Upper limb - Injury/Fracture/Dislocation of Other regional musculoskeletal disease Musculoskeletal disease - Regional / Localised - Other / type not known

This Viral, At-Home Fitness Test Claims to Predict Longevity—but There's a Catch
This Viral, At-Home Fitness Test Claims to Predict Longevity—but There's a Catch

Yahoo

time6 hours ago

  • Yahoo

This Viral, At-Home Fitness Test Claims to Predict Longevity—but There's a Catch

Dimensions/Getty Images New blood tests, scans, and fitness trackers that purport to predict longevity are rolling out all the time, but if you've scrolled TikTok recently, you might be surprised to see a much lower-tech way getting some buzz: how well you fare in simply trying to haul your butt off the floor. It's all based on the takeaway from a study published in the European Journal of Preventive Cardiology that's been making the rounds. In it, researchers had more than 4,000 people do something they dubbed the 'sitting-rising' test and then followed up with them for over a decade. They found a link between how easily people were able to get up off the floor and how long they lived. The task sounds simple, but, as I learned firsthand, it's really not. To get a perfect score on the test, you need to be able to get from a position on the floor—usually cross-legged—to standing without using a hand, elbow, or knee to help. As a former competitive athlete who can't say no to a challenge, I needed to try this (and gain a perfect score) once it came across my FYP. To my surprise, it was hard. While I was able to get it done, I had to give myself a mental pep talk before each attempt. Pulling this test off is trickier than it sounds—it requires a combination of strength, balance, and flexibility, and I struggle to even touch my toes. So that made me wonder: How legit is it, really, in predicting your, um, ultimate demise? Does bombing the test mean you're going to keel over any second? I checked in with longevity experts and fitness pros to find out. One of the benefits of the sitting-rising test is you can do it right at home: Sit on the floor with your legs crossed in front of you and then try to get back up unassisted. The goal is to do this with as little support as possible, test inventor and lead study author Claudio Gil S Araújo, MD, a sports and exercise physician from the Exercise Medicine Clinic Clinimex in Rio de Janeiro, tells SELF. (Check out this handy YouTube video Dr. Araújo and his fellow researchers created to break it down in more detail.) The test is scored from zero to 10, with points assigned for sitting and rising added together. You'll be docked a point for each knee, hand, or forearm you use during the test, along with half-points if you're unsteady (say, you stumble when you get up). 'If you're an eight, why did you lose a point? It may mean that you used one hand to sit and one hand to rise,' Dr. Araújo says. In the study, the researchers discovered a link between how well people scored on the test and their risk of dying during a follow-up of about 12 years. In all, about 16% of the participants died during that period—but only 4% of folks who aced the test with a perfect 10 did so. (On the other end of the spectrum, people who got a four or less had a death rate of 42% during that time.) Okay, but…why? The test measures a few different things that are linked to better health and longevity, study co-author Jonathan Myers, PhD, a clinical professor at Stanford University and a health research scientist at the Palo Alto VA Health Care System, tells SELF. 'When we think of 'fitness,' people usually think of 'aerobic' or cardiorespiratory fitness,' he says. 'Over the last three decades or so, cardiorespiratory fitness has become recognized as a powerful predictor of health outcomes—in many studies, it is even more powerful than the traditional risk factors such as smoking, hypertension, or [high cholesterol].' Cardiorespiratory fitness is important, sure—it's considered a strong indicator of overall health, along with being linked to a lower risk of developing certain diseases. But fitness is more broad than that, and includes things like strength and balance, Dr. Myers says. Strength has been shown to help with daily living (think: being able to carry your own groceries), while balance helps to protect against falls, Dr. Araújo explains. These skills are important for longevity, and they're something that Hannah Koch, PT, DPT, physical therapist at Michigan State University Health Care, tells SELF she checks with older patients, along with their range of motion. The sitting-rising test looks at strength, power, and balance, all in one move. So basically, you're getting more bang for your buck, looking at all of these factors at once. Added bonus: It can also give some insight on your cardiovascular health, Jennifer Wong, MD, cardiologist and medical director of Non-Invasive Cardiology at MemorialCare Heart and Vascular Institute at Orange Coast Medical Center in Fountain Valley, California, tells SELF. 'One could not do this after certain types of strokes or if too weak from poor overall health,' she adds. While the test is predictive, it's by no means perfect: There are some flaws with it. 'The test does not identify the underlying cause of poor performance,' Anna A. Manns, PT, DPT, lead physical therapist at University Hospital in New Jersey, tells SELF. Meaning, it can't tell if you struggle with getting up due to joint pain, an injury, or the fact that you went hard at the gym yesterday—and those factors don't necessarily have an impact on your longevity. It's also possible to game the test, say, by 'compensating with upper-body movement or momentum by using arm swings or trunk movement to 'cheat' the test,' Dr. Mann says, which would 'mask true lower-limb weakness.' The test also only looks at lower-body function and core strength, so it doesn't gauge your overall fitness, upper-body strength or endurance, 'all of which are important for full functional capacity,' she adds. While the sitting-rising test has a link with longevity, there are plenty of others that healthcare providers use regularly. Simple hand-grip tests, which measure grip strength, are a 'powerful predictor of mortality,' Dr. Myers says. Case in point: A 2015 study published in The Lancet found that grip strength was better at predicting someone's odds of dying from heart disease or other causes during the follow-up than systolic blood pressure, which is usually used to gauge cardiovascular health. Balance tests, like the ability to stand on one leg for 10 seconds or longer, can also be helpful, Dr. Myers says. Koch also flags the Five Times Sit-to-Stand Test (5TSTS) as a useful way to check a person's lower-body strength and balance. It's similar to the sitting-rising test, but has people get up from a chair versus the floor five different times. The Timed Up and Go (TUG) test, which has people get up from a chair, walk a short distance, turn around, walk back, and sit back down while being timed, is useful too, says Manns. 'Together, these tests provide a patient picture of overall physical function and longevity,' Manns says. That said, they're still only a part of the overall picture of your health. There's no reason to get down on yourself if you don't do well on the sitting-rising test—not getting a perfect 10 on the sitting-rising test certainly doesn't mean you're doomed. But it could clue you in on areas of fitness to work on, Dr. Araújo says. That may mean working on balance training, flexibility, or building power. 'This helps a lot to get people motivated,' Dr. Araújo says. Dr. Myers agrees that your mobility, strength, flexibility, and balance can usually be improved with practice and training. 'Individuals who don't perform well on these tests can improve their performance by strengthening lower body muscles, and specific exercises can be targeted to improve flexibility, balance, gait, and mobility,' he says. Albert Matheny, CSCS, cofounder of SoHo Strength Lab, suggests focusing on things like squats, single-leg exercises like lunges, and even balancing on one leg to hit these areas. It's also important to remember that these tests are only part of the puzzle: There are a bunch of health-promoting behaviors out there that have nothing to do with how well you can get up off the floor—or even how well you move in general. While physical activity is important, other things, like eating a high-quality diet, minimizing stress, getting plenty of sleep, and adopting other healthy lifestyle habits like avoiding smoking and minimizing alcohol, also come in handy. Together, these can help you be your healthiest self. 'The sitting-rising test is a good screening tool,' Dr. Araújo says. 'There's a lot we can do to move forward after that.' Related: 6 Daily Habits Doctors Say Will Help You Live Longer 5 Ways Strong Friendships Can Benefit Your Health as You Get Older Exactly How Your Skin Changes in Your 40s, 50s, and 60s Get more of SELF's great fitness coverage delivered right to your inbox—for free. Originally Appeared on Self

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store